Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Stock Information for Lipocine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lipocine Inc.

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine to Present at 36th Annual Roth Conference
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
Lipocine to Present at Biotech Showcase 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.